Amgen, Allergan join Rituxan biosimilar challenge with FDA f...

First Rituxan biosimilar Truxima set to make its debut in US

Humira tops list of drugs with unwarranted US price hikes

Roche raises 2019 outlook, shrugging off biosimilar threat

Celgene bags FDA okay for Revlimid combo in lymphoma

Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use alongside Roche’s Rituxan for two additional forms of indolent non-Hodgkin

Genentech’s Rituxan approved for rare skin disease

The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.